Medical Weight Loss Treatment for New York Residents
Medically Supervised Weight Loss, Delivered Online
OmniRx Health providers are licensed by the New York State Education Department to deliver telehealth across the Empire State.
Whether you're in New York City, Albany, or anywhere across New York — our board-certified providers are ready to see you.
Medical Weight Loss Treatment in New York
Our board-certified providers prescribe FDA-approved and physician-developed weight loss medications including GLP-1 agonists, customized to your health profile and goals.
No office visits required — 100% online consultations
FDA-approved and physician-developed medications
Personalized dosing protocols adjusted to your response
Ongoing provider support and check-ins throughout treatment
Medications shipped directly to your door from licensed pharmacies
New York is a world unto itself—from the skyscrapers of Manhattan to the farms of the Finger Lakes, the tech corridors of the Hudson Valley to the winter sports meccas of the Adirondacks. OmniRx Health serves every New Yorker. Whether you're a Wall Street professional who can't take time off, an upstate family far from specialists, or an artist in Brooklyn seeking convenient care, our telehealth platform delivers Empire State-quality medicine to wherever you are.
Available Treatments in New York
Our board-certified providers in New York can prescribe and manage the following treatment options
Semaglutide
Semaglutide is a GLP-1 receptor agonist that reduces appetite and slows gastric emptying, helping patients achieve significant, sustained weight loss. Originally developed for type 2 diabetes management, semaglutide has become one of the most clinically effective weight loss medications available.
Tirzepatide
Tirzepatide is a dual GLP-1 and GIP receptor agonist that produces even greater weight loss than semaglutide alone. It addresses appetite, blood sugar regulation, and metabolic rate through two complementary hormonal pathways for superior outcomes.
Tesofensine
Tesofensine is a triple monoamine reuptake inhibitor that suppresses appetite and boosts metabolism through dopamine, norepinephrine, and serotonin pathways. Originally developed as an anti-Parkinson's agent, it showed exceptional weight loss properties in clinical trials.
Retatrutide
Retatrutide (LY3437943) is a 39-amino acid synthetic peptide and triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Currently in Phase 3 clinical trials (TRIUMPH program), it produced 24.2% average weight loss at 48 weeks in Phase 2 data — the highest weight reduction observed in any peptide trial to date. Listed by OmniRx for research-use only (RUO).
Telehealth Regulations in New York
State Licensing
OmniRx Health providers are licensed by the New York State Education Department to deliver telehealth across the Empire State.
Telehealth Law
New York has comprehensive telehealth laws that support virtual care delivery across the state's diverse urban and rural communities.
Pharmacy Access
New York's vast pharmacy network from NYC to Buffalo ensures prescription access, with specialized compounding pharmacies available throughout.
Insurance Notes
New York mandates telehealth coverage, including requirements for commercial insurers and Medicaid to cover virtual visits.
Frequently Asked Questions
Common questions about medical weight loss and telehealth access in New York
Explore Related Medical Weight Loss Pages
Direct links to specific treatments and other states.